VANCOUVER, June 11, 2019 /CNW/ - Sirona Biochem Corp.
(TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce
that it will assess its novel skin lightener, TFC-1067, at a
concentration 3 times higher than what was used in the previous
clinical trial. Higher dosing is expected to have increased
efficacy, but also the potential to work more quickly than the
clinically effective dose established for TFC-1067. This positive
development is of substantial commercial interest to potential
cosmetic partners in North America
and China who share Sirona's goal
to maximize efficacy without compromising safety.
Previous maximum dosing levels were limited due to technical
issues with the standard regulatory in vitro test used to
assess TFC-1067 for skin irritation. A solution to these technical
issues has been developed. Sirona's consultant safety assessor at
CEHTRA (https://www.cehtra.com) has now recommended further testing
with up to a 3 times higher dose. Several higher doses will be
assessed by Idea Lab (https://www.ideatestsgroup.com), experts in
safety testing of cosmetics. If the in vitro results of the
higher concentrations continue to show no evidence for skin
irritation, Sirona will proceed to preparation for clinical testing
on humans.
"The clinical effect of TFC-1067 to lessen dark spots or have an
overall brightening effect is largely dose dependent", reports Dr.
Howard Verrico, CEO of Sirona
Biochem. "We anticipate TFC-1067 will be used at higher doses
without adverse effects. While we are pleased with the excellent
clinical results achieved so far, being able to test at
significantly higher concentrations will likely lead to better
clinical effectiveness, potentially faster results and a better
range of consumer dosing options."
"We knew the standard regulatory tests prevented us from
utilizing the full potential of TFC-1067 as a skin lightener. We
anticipate we will proceed in the future to test our improved
formulation combined with higher concentrations of TFC-1067 in
further clinical trials. Such testing can be conducted either
independently by Sirona or through our anticipated partnerships",
Dr. Verrico added.
The global skin lightening market is expected to reach
US$31.2 Billion by
2024.1
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French
national scientific awards and European Union and French government
grants. For more information, please
visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this press release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
|
|
|
|
|
|
|
|
|
|
|
|
1 https://www.strategyr.com/MarketResearch/Skin_Lighteners_Market_Trends.asp
|
SOURCE Sirona Biochem Corp.